Oflajet Plus Tablet is a combination pharmaceutical formulation containing Lactobacillus (120 million spores), Ofloxacin (200 mg), Ornidazole (500 mg), and Saccharomyces boulardii (2 million spores), designed to provide a comprehensive approach to the treatment of gastrointestinal infections. Ofloxacin, a fluoroquinolone antibiotic, exhibits broad-spectrum antibacterial activity against Gram-positive and Gram-negative pathogens by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, thereby preventing bacterial replication. Ornidazole, a nitroimidazole derivative, offers potent antiprotozoal and anaerobic antibacterial effects, effectively targeting protozoa and anaerobic bacteria commonly implicated in gastrointestinal infections. The inclusion of Lactobacillus and Saccharomyces boulardii, both probiotic agents, aids in restoring and maintaining normal gut flora balance disrupted by infection or antibiotic therapy, thereby reducing the risk of antibiotic-associated diarrhea and promoting intestinal health. Oflajet Plus is indicated for the treatment of mixed bacterial and protozoal infections of the gastrointestinal tract, including acute diarrhea, dysentery, and amoebiasis. It should be used under medical supervision, with consideration given to patient history, potential drug interactions, and contraindications such as hypersensitivity to fluoroquinolones or nitroimidazoles. The combined antimicrobial and probiotic action of Oflajet Plus facilitates effective eradication of pathogens while supporting gastrointestinal mucosal integrity.